News

Regulatory affairsRegulatory Round-up - May 2026
Filter:AllPress ReleaseCell TherapiesGene TherapiesDigital and AutomationSpin-outs, Start-ups, Sector investmentManufacturingRegulatory affairsSkills and Training
Year:All2026202520242023 →
CGT Catapult supports translation of research across the UK through engagement with key academic hubsCGT Catapult supports translation of research across the UK through engagement with key academic hubsFlagship EU programme launchedFlagship EU programme launchedFebruary news: Where will we see you next month?February news: Where will we see you next month?January news: Agenda confirmed for manufacturing workshopJanuary news: Agenda confirmed for manufacturing workshopPress Release: CGT Catapult Celebrates First Successful Months of Novel Apprenticeship Programme to Secure Future Skills for Advanced TherapiesPress Release: CGT Catapult Celebrates First Successful Months of Novel Apprenticeship Programme to Secure Future Skills for Advanced TherapiesAutolus approved to manufacture clinical trial products at the Cell and Gene Therapy Catapult manufacturing centreAutolus approved to manufacture clinical trial products at the Cell and Gene Therapy Catapult manufacturing centreRegulatory news - February 2019Regulatory news - February 2019Regulatory news - January 2019Regulatory news - January 2019Press release: Surge in cell and gene therapy trials highlight the UK’s leading position as developmental hub in this innovative industryPress release: Surge in cell and gene therapy trials highlight the UK’s leading position as developmental hub in this innovative industryPress release: CGT Catapult and pHion Therapeutics Announce Licencing Agreement for the RALA TechnologyPress release: CGT Catapult and pHion Therapeutics Announce Licencing Agreement for the RALA TechnologyRegulatory news - November 2018Regulatory news - November 2018Midlands - Wales ATTC to lead ground-breaking research into patient experience of cell therapiesMidlands - Wales ATTC to lead ground-breaking research into patient experience of cell therapies